Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ABC294640||Yeliva|Opaganib|ABC-294640|ABC 294640||Yeliva (ABC294640) is a selective inhibitor of sphingokinase 2 (SK2), which results in decreased SK2 activity, leading to reduced cell signaling and tumor cell growth (PMID: 26271487).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||ABC294640||Phase I||Actionable||In a Phase I trial, treatment with ABC294640 in patients with advanced solid tumors resulted in antitumor efficacy, including stable disease in six patients and a partial response in a patient with cholangiosarcoma (PMID: 28420720).||28420720|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02229981||Phase Ib/II||ABC294640||An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma||Withdrawn|
|NCT02939807||Phase II||ABC294640||A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma||Withdrawn|
|NCT03377179||Phase II||ABC294640||A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma||Recruiting|
|NCT02757326||Phase Ib/II||ABC294640||ABC294640 in Refractory / Relapsed Multiple Myeloma||Terminated|